Shares of GW Pharmaceuticals PLC- (NASDAQ:GWPH) have been assigned a consensus recommendation of “Buy” from the thirteen research firms that are covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell rating, four have assigned a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is $147.38.
A number of brokerages have recently issued reports on GWPH. Goldman Sachs Group reissued a “neutral” rating and issued a $124.00 price objective on shares of GW Pharmaceuticals PLC- in a research note on Friday, October 6th. Bank of America reduced their price objective on GW Pharmaceuticals PLC- from $160.00 to $158.00 and set a “buy” rating for the company in a research report on Tuesday, November 14th. Cantor Fitzgerald reaffirmed a “buy” rating and set a $208.00 price target on shares of GW Pharmaceuticals PLC- in a report on Monday, November 20th. ValuEngine upgraded GW Pharmaceuticals PLC- from a “sell” rating to a “hold” rating in a research report on Friday, September 1st. Finally, Evercore ISI assumed coverage on GW Pharmaceuticals PLC- in a report on Wednesday, August 16th. They set an “outperform” rating and a $154.00 target price on the stock.
GW Pharmaceuticals PLC- (NASDAQ GWPH) opened at $124.49 on Friday. GW Pharmaceuticals PLC- has a 1-year low of $92.65 and a 1-year high of $136.95. The company has a debt-to-equity ratio of 0.02, a quick ratio of 10.26 and a current ratio of 10.39.
GW Pharmaceuticals PLC- Company Profile
GW Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing therapeutics from its cannabinoid product platform in a range of disease areas. The Company’s lead cannabinoid product candidate is Epidiolex, which is a liquid formulation of pure plant-derived cannabidiol (CBD).
Receive News & Ratings for GW Pharmaceuticals PLC- Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC- and related companies with MarketBeat.com's FREE daily email newsletter.